| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021119733 | 2021-09-23 | ||
| PCT/CN2022/120422WO2023045995A1 (en) | 2021-09-23 | 2022-09-22 | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents |
| Publication Number | Publication Date |
|---|---|
| MX2024003477Atrue MX2024003477A (en) | 2024-04-05 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003477AMX2024003477A (en) | 2021-09-23 | 2022-09-22 | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents. |
| Country | Link |
|---|---|
| EP (1) | EP4380624A1 (en) |
| JP (1) | JP2024535374A (en) |
| KR (1) | KR20240082358A (en) |
| CN (1) | CN116916963A (en) |
| AU (1) | AU2022349576A1 (en) |
| CA (1) | CA3228838A1 (en) |
| IL (1) | IL310844A (en) |
| MX (1) | MX2024003477A (en) |
| TW (1) | TW202327658A (en) |
| WO (1) | WO2023045995A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025109631A1 (en)* | 2023-11-23 | 2025-05-30 | Micro Crispr Pvt. Ltd. | Synthetic delivery systems and conjugates thereof |
| WO2025113470A1 (en)* | 2023-11-27 | 2025-06-05 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of transthyretin (ttr) |
| WO2025146138A1 (en)* | 2024-01-04 | 2025-07-10 | Shanghai Rona Therapeutics Co., Ltd. | Ligands for extrahepatic delivery |
| WO2025168022A1 (en)* | 2024-02-07 | 2025-08-14 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of huntingtin (htt) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011038356A2 (en)* | 2009-09-25 | 2011-03-31 | Johns Hopkins University | Novel liver-targeting agents and their synthesis |
| TWI553017B (en)* | 2012-12-28 | 2016-10-11 | 行政院原子能委員會核能研究所 | A novel gall bladder imaging agent and its preparation method |
| BR112015027321A8 (en)* | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES |
| US20170304459A1 (en)* | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
| MA45478A (en)* | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS |
| WO2020191183A1 (en)* | 2019-03-21 | 2020-09-24 | Mitotherapeutix Llc | Multivalent ligand clusters for targeted delivery of therapeutic agents |
| Publication number | Publication date |
|---|---|
| TW202327658A (en) | 2023-07-16 |
| KR20240082358A (en) | 2024-06-10 |
| JP2024535374A (en) | 2024-09-30 |
| WO2023045995A1 (en) | 2023-03-30 |
| CN116916963A (en) | 2023-10-20 |
| EP4380624A1 (en) | 2024-06-12 |
| IL310844A (en) | 2024-04-01 |
| CA3228838A1 (en) | 2023-03-30 |
| AU2022349576A1 (en) | 2024-02-15 |
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003477A (en) | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents. | |
| Mirzaei et al. | Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: current status with an emphasis on delivery systems | |
| Ramzy et al. | Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors | |
| MX2022008455A (en) | Nanomaterials. | |
| BR112020022546A8 (en) | extra-hepatic delivery | |
| MX2022008629A (en) | Lipid nanoparticles for in-vivo drug delivery, and uses thereof. | |
| NZ776256A (en) | Therapeutic methods | |
| PH12017501501A1 (en) | Compositions and methods for inhibiting expression of tmprss6 gene | |
| BR112019002117A2 (en) | rnai agent against hepatitis b virus infection | |
| MX2023001541A (en) | Systemic delivery of oligonucleotides. | |
| PH12022552327A1 (en) | Compositions and methods for targeted rna delivery | |
| NZ601737A (en) | Compositions for targeted delivery of sirna | |
| WO2018140920A8 (en) | Compositions and methods for inhibition of factor xii gene expression | |
| SI2999785T1 (en) | Serpina1 irna compositions and methods of use thereof | |
| MX2012012668A (en) | High shear application in drug delivery. | |
| WO2008109105A3 (en) | Methods and compositions for improved therapeutic effects with sirna | |
| WO2018124548A3 (en) | Complex for drug delivery and stabilization and preparation method thereof | |
| WO2020097511A3 (en) | Messenger rna therapy for treatment of ocular diseases | |
| SG194175A1 (en) | Polymer conjugated prostaglandin analogues | |
| MX2023007734A (en) | Antibody compositions and methods of use thereof. | |
| WO2008109432A3 (en) | Therapeutic targeting of interleukins using sirna in neutral liposomes | |
| EP4218770A3 (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
| WO2018175323A4 (en) | Gemcitabine derivatives for cancer therapy | |
| BR112023027308A2 (en) | PIKFYVE ANTISENSE OLIGONUCLEOTIDES | |
| MX2024011241A (en) | Galnac compositions for improving sirna bioavailability |